TELA Bio to Announce First Quarter 2022 Financial Results
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its first quarter 2022 financial results on May 10, 2022, at 4:30 p.m. ET. The call will provide insights into the company’s performance in soft-tissue reconstruction solutions that prioritize patient anatomy restoration. Interested parties can access the conference by dialing specific numbers for U.S./Canada and international participants, or via the company's investor website. TELA emphasizes its commitment to innovative, economically effective healthcare solutions while cautioning that forward-looking statements carry inherent risks.
- Conference call scheduled to discuss Q1 2022 results, providing transparency to investors.
- Focus on innovative soft-tissue reconstruction products could enhance clinical outcomes and market position.
- Forward-looking statements carry risks and uncertainties that may impact future performance.
MALVERN, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the company will report first quarter 2022 financial results on Tuesday, May 10, 2022. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
The conference call can be accessed by dialing 855-548-1219 for participants in the U.S. or Canada and 409-217-8881 for international callers, using conference ID 8249526. A live and archived webcast of the event can be accessed via the Events & Presentations page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Greg Chodaczek
347-620-7010
ir@telabio.com
FAQ
When will TELA Bio report its first quarter 2022 financial results?
What time is the TELA Bio conference call for financial results?
How can I access TELA Bio's conference call?
What is the focus of TELA Bio as a medical technology company?
What should investors be cautious about regarding TELA Bio's forward-looking statements?
